Close this search box.

Quantifying impact of accelerated approval on life extension

ARTICLE | Regulation

Study attributes over 260,000 additional life years in 2006-22 to accelerated approval

By Steve Usdin, Washington Editor, and Selina Koch, Executive Editor

April 30, 2024 10:11 PM UTC

Accelerated approval has provided massive benefits to cancer patients, contributing over 260,000 additional life years from 2006 to 2022, according to a study published in the Journal of the National Comprehensive Cancer Network. That number is far from firm, and is almost certainly an underestimate.

Documenting the benefits from accelerated approval could help defend the pathway against academic critics, and counter misleading research that has led medical journals and news organizations to inaccurately report that a large proportion of accelerated approval cancer drugs have not extended survival.